# EDGAR Filing Document

**Accession Number:** 0001835205
**File Stem:** 0001104659-23-031638
**Filing Date:** 2023-3
**Character Count:** 2958
**Document Hash:** ac01be4c76c6c91ab0cac95b5eaf4e5c
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001104659-23-031638.hdr.sgml**: 20230313

**ACCESSION NUMBER**: 0001104659-23-031638

**CONFORMED SUBMISSION TYPE**: 15-12G

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20230313

**DATE AS OF CHANGE**: 20230313

**EFFECTIVENESS DATE**: 20230313

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** IBERE PHARMACEUTICALS
- **CENTRAL INDEX KEY:** 0001835205
- **STANDARD INDUSTRIAL CLASSIFICATION:** BLANK CHECKS [6770]
- **IRS NUMBER:** 981564986
- **STATE OF INCORPORATION:** E9
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 15-12G
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-40119
- **FILM NUMBER:** 23726293

**BUSINESS ADDRESS:**
- **STREET 1:** 2005 MARKET STREET, SUITE 2030
- **CITY:** PHILADELPHIA
- **STATE:** PA
- **ZIP:** 19103
- **BUSINESS PHONE:** 267-765-3222

**MAIL ADDRESS:**
- **STREET 1:** 2005 MARKET STREET, SUITE 2030
- **CITY:** PHILADELPHIA
- **STATE:** PA
- **ZIP:** 19103

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 15**

**CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION<br> UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934<br> OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d)<br> OF THE SECURITIES EXCHANGE ACT OF 1934.**

Commission File Number **<u>001-40119</u>**

**Ibere Pharmaceuticals**

(Exact name of registrant as specified in its charter)

**2005 Market Street, Suite 2030**

**Philadelphia, PA 19103**

(Address, including zip code, and telephone number, including area code, of registrant's principal executive offices)

**Units, each consisting of one Class A ordinary share, $0.0001 par value, and one-half of one redeemable warrant;**

**Class A ordinary share, $0.0001 par value;**

**Warrants, each whole warrant exercisable for one Class A ordinary share for $11.50 per share**

(Title of each class of securities covered by this Form)

**None.**

(Titles of all other classes of securities for which a duty to file reports under section 13(a) or 15(d) remains)

Please place an X in the box(es) to designate the appropriate rule provision(s) relied upon to terminate or suspend the duty to file reports:

---

| | |
|:---|:---|
| Rule 12g-4(a)(1) | ⌧ |
| Rule 12g-4(a)(2) | ◻ |
| Rule 12h-3(b)(1)(i) | ⌧ |
| Rule 12h-3(b)(1)(ii) | ◻ |
| Rule 15d-6 | ◻ |
| Rule 15d-22(b) | ◻ |

---

Approximate number of holders of record as of the certification or notice date: 1

Pursuant to the requirements of the Securities Exchange Act of 1934, Ibere Pharmaceuticals has caused this certification/notice to be signed on its behalf by the undersigned duly authorized person.

---

| | | | |
|:---|:---|:---|:---|
|  | **IBERE PHARMACEUTICALS** | **IBERE PHARMACEUTICALS** | **IBERE PHARMACEUTICALS** |
| Date: <u>March 13, 2023</u> | By: | /s/ Osagie Imasogie | /s/ Osagie Imasogie |
|  |  | Name: | Osagie Imasogie |
|  |  | Title: | Chief Executive Officer |

---